The Technical AnalystExchange: STO Sector: Healthcare Industry: Medical Instruments & Supplies
FluoGuide A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.60% SEK50.80
America/New_York / 17 mai 2024 @ 09:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 619.66 mill |
| EPS: | -5.03 |
| P/E: | -10.10 |
| Earnings Date: | May 30, 2024 |
| SharesOutstanding: | 12.20 mill |
| Avg Daily Volume: | 0.0088 mill |
| RATING 2024-05-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -10.10 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.49x |
| Company: PE -10.10 | industry: PE 20.76 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK1.387 (-97.27%) SEK-49.41 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 48.09 - 53.51 ( +/- 5.33%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK50.80 (1.60% ) |
| Volume | 0.0046 mill |
| Avg. Vol. | 0.0088 mill |
| % of Avg. Vol | 52.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FLUO.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FLUO.ST
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.